FOXP4-mediated induction of PTK7 activates the Wnt/β-catenin pathway and promotes ovarian cancer development
Jing Ji,Qilan Qian,Wenhao Cheng,Xiaoqing Ye,Aixin Jing,Shaojie Ma,Yuanyuan Ding,Xinhui Ma,Yasong Wang,Qian Sun,Xiujun Wang,Yulu Chen,Lan Zhu,Qing Yuan,Menghan Xu,Jingting Qin,Lin Ma,Jiayan Yang,Meiqi Zhang,Ting Geng,Sen Wang,Dan Wang,Yizhuo Song,Boyu Zhang,Yuting Xu,Linyu Xu,Shunfang Liu,Wei Liu,Bin Liu
DOI: https://doi.org/10.1038/s41419-024-06713-7
2024-05-13
Abstract:Ovarian cancer (OV) poses a significant challenge in clinical settings due to its difficulty in early diagnosis and treatment resistance. FOXP4, belonging to the FOXP subfamily, plays a pivotal role in various biological processes including cancer, cell cycle regulation, and embryonic development. However, the specific role and importance of FOXP4 in OV have remained unclear. Our research showed that FOXP4 is highly expressed in OV tissues, with its elevated levels correlating with poor prognosis. We further explored FOXP4's function through RNA sequencing and functional analysis in FOXP4-deficient cells, revealing its critical role in activating the Wnt signaling pathway. This activation exacerbates the malignant phenotype in OV. Mechanistically, FOXP4 directly induces the expression of protein tyrosine kinase 7 (PTK7), a Wnt-binding receptor tyrosine pseudokinase, which causes abnormal activation of the Wnt signaling pathway. Disrupting the FOXP4-Wnt feedback loop by inactivating the Wnt signaling pathway or reducing FOXP4 expression resulted in the reduction of the malignant phenotype of OV cells, while restoring PTK7 expression reversed this effect. In conclusion, our findings underscore the significance of the FOXP4-induced Wnt pathway activation in OV, suggesting the therapeutic potential of targeting this pathway in OV treatment.